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costs. In this model, prescription non-procurement was
more likely to be reported in the Medicare-only popula-
tion (OR: 1.47; 95% CI 1.46–1.48) and in the Medicare
plus Medicaid population (OR: 1.11; 95% CI 1.10–1.12)
as compared to respondents with Medicare plus private
insurance coverage. CONCLUSIONS: Signiﬁcantly dif-
ferent rates of persons who forego ﬁlling a prescription
for cost reasons were observed among Medicare beneﬁ-
ciaries. More vulnerable groups of seniors were identiﬁed.
Dual eligible Medicare/Medicaid enrollees and those with
Medicare alone are more likely to restrict medication 
procurement due to cost.
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OBJECTIVES: 1) To explore 1-year persistence pattern
of Overactive Bladder/Urinary Incontinence (OAB/UI)
medication treatment; 2) to discover factors associated
with persistence; and 3) to investigate the beneﬁt of reﬁll
adherence on urinary track infection (UTI). METHODS:
Retrospective analyses on continuously enrolled adult
patients diagnosed with OAB/UI and received at least one
OAB/UI medication from July 1999 to April 2001 (with
6-month run-in period and 1-year follow-up period) are
employed. Time to discontinuity, deﬁned as the period
from the index date to the discontinuity date (when any
medication-uncovered interval is longer than 30 days), 
is used to describe the persistence pattern of patients.
Adherence is measured by medication possession ratio
(MPR). A Cox Proportional Hazard model is applied to
reveal risk factors of non-persistence. A logistic regression
is used to examine the relationship of those same factors
with reﬁll adherence and to assess the effect of adherence
on UTI incidence rate. RESULTS: Of 6518 eligible
patients, 26.8% have only 1 prescription. 5751 patients
(88.2%) discontinue within the following year, among
which, 92.2% fail to continue treatment after 183 days.
Only 952 patients (14.6%) exhibit good adherence (MPR
>= 0.8). The mean MPR of the whole cohort is 0.39 and
the median is 0.24. Signiﬁcant predictors of higher per-
sistence include Caucasians, 75 years old or above, prior
medication use, and initiating extended-release form of
drug. Patients with prior prescription of antidepressant or
diagnosis of depression show lower persistence. Similar
results are found for adherence. Logistic regression indi-
cates that good reﬁll adherence reduces the risk of being
diagnosed with UTI by 33% in the post-treatment period
(P = 0.0008, OR = 0.672). CONCLUSIONS: Both 
persistence of OAB/UI medication and reﬁll adherence 
are low, suggesting the need to develop effective inter-
ventions in OAB/UI and UTI.
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OBJECTIVES: Medication non-compliance has been a
growing concern for healthcare management and can
result in progression of cardiovascular disease (CV) and
an increase in economic burden. To develop models to
predict the risk for future medication non-compliance
among patients with hypertension and hyperlipidemia.
METHODS: Two predictive models were constructed
using pharmacy and medical claims from 2380 patients
newly treated with anti-hypertensive medications and
3387 patients newly treated with statins in a managed
care setting. The outcomes of interest were the future
medication compliance rates for both disease states over
a one-year follow-up period. The potential predictors of
compliance included patient characteristics such as age,
gender, type of insurance plan, Chronic Disease Score
(CDS), presence of select comorbidities, copayments,
total medication burden, hospital encounters, outpatient
physician encounters, and initial compliance (0–3 months
of therapy immediately before the follow-up period).
Linear regression models were applied to construct the
models. Each population was randomly split by a 2 to 1
ratio to facilitate spilt-sample validation of the models.
RESULTS: Based on the hypertension model, age, gender,
total co-payments, total medication burden, and initial
compliance showed signiﬁcant relationship with compli-
ance (R2 = 0.45). Based on the hyperlipidemic model, age,
gender, presence of a second CV condition (e.g. angina),
outpatient physician encounters, co-payments at drug ini-
tiation, total medication burden, and initial compliance
demonstrated signiﬁcant relationship with compliance
(R2 = 0.43). In both populations, initial compliance was
the strongest predictor of sustained compliance. CON-
CLUSION: These models can serve as a useful tool to
guide providers in promoting medication compliance.
Both models suggest that assisting the patient to establish
compliant behavior within the ﬁrst three months of a new
treatment regimen can signiﬁcantly inﬂuence sustained
medication adherence with CV medications.
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